Nature Communications (May 2022)
Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19
- Ting Lu,
- Rui Ma,
- Wenjuan Dong,
- Kun-Yu Teng,
- Daniel S. Kollath,
- Zhiyao Li,
- Jinhee Yi,
- Christian Bustillos,
- Shoubao Ma,
- Lei Tian,
- Anthony G. Mansour,
- Zhenlong Li,
- Erik W. Settles,
- Jianying Zhang,
- Paul S. Keim,
- Bridget M. Barker,
- Michael A. Caligiuri,
- Jianhua Yu
Affiliations
- Ting Lu
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Rui Ma
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Wenjuan Dong
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Kun-Yu Teng
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Daniel S. Kollath
- Pathogen and Microbiome Institute, Northern Arizona University
- Zhiyao Li
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Jinhee Yi
- Pathogen and Microbiome Institute, Northern Arizona University
- Christian Bustillos
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Shoubao Ma
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Lei Tian
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Anthony G. Mansour
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Zhenlong Li
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Erik W. Settles
- Pathogen and Microbiome Institute, Northern Arizona University
- Jianying Zhang
- Department of Computational and Quantitative Medicine, City of Hope National Medical Center
- Paul S. Keim
- Pathogen and Microbiome Institute, Northern Arizona University
- Bridget M. Barker
- Pathogen and Microbiome Institute, Northern Arizona University
- Michael A. Caligiuri
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Jianhua Yu
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center
- DOI
- https://doi.org/10.1038/s41467-022-30216-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
Severe COVID-19 requires immediate and targeted intervention that is efficient against SARS-CoV-2 and its variants. Authors show here the therapeutic potential of engineered natural killer cells that simultaneously express a chimeric antigen receptor targeting the spike protein of SARS-CoV-2, and IL-15, a cytokine that enhances the function and survival of their own.
